Insights into the success and failure of systemic therapy for hepatocellular carcinoma.

Published on Aug 1, 2019in Nature Reviews Gastroenterology & Hepatology29.848
· DOI :10.1038/S41575-019-0179-X
Jordi Bruix115
Estimated H-index: 115
(University of Barcelona),
Leonardo G. Da Fonseca5
Estimated H-index: 5
(University of Barcelona),
Maria Reig33
Estimated H-index: 33
(University of Barcelona)
Sources
Abstract
Systemic treatment for hepatocellular carcinoma (HCC) has been boosted by the incorporation of new agents after many negative phase III trials in the decade since the approval of sorafenib. Sorafenib introduced the concept that targeting specific hallmarks of hepatocarcinogenesis could modify the dismal prognosis of this disease, with the drug remaining a cornerstone in the upfront therapy for advanced HCC. The design of clinical trials in this malignancy is complicated by important obstacles related to patient selection, prognostic assessment and the need for endpoints that correlate with improvement in survival outcomes. In addition, the currently used criteria to determine treatment response or progression might prevent physicians from making appropriate clinical judgements and interpreting evidence arising from trials. In this Review, we discuss the advances in systemic therapy for HCC and critically review trial designs in HCC. Although novel therapies, such as new targeted agents and immunotherapies, are being rapidly incorporated, it is paramount to design future clinical trials based on the lessons learned from past failures and successes.
📖 Papers frequently viewed together
4,989 Citations
816 Citations
31 Citations
References103
Newest
#1Josep M. Llovet (University of Barcelona)H-Index: 120
#2Robert Montal (University of Barcelona)H-Index: 8
Last. Augusto Villanueva (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 63
view all 3 authors...
Summary Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. Around half of patients with HCC will receive systemic therapies during their life span. The pivotal positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative studies with drugs leading to marginal antitumoral efficacy, toxicity, or trials with a lack of enrichment strategies. This trend has changed over the last 2 years with several compounds, such as lenvatinib (in...
67 CitationsSource
#1Roser Pinyol (University of Barcelona)H-Index: 13
#2Robert Montal (University of Barcelona)H-Index: 8
Last. Josep M. LlovetH-Index: 120
view all 30 authors...
Objective Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achieve its primary endpoint of improving recurrence-free survival (RFS). The biomarker companion study BIOSTORM aims to define (A) predictors of recurrence prevention with sorafenib and (B) prognostic facto...
85 CitationsSource
#1Richard S. Finn (UCLA: University of California, Los Angeles)H-Index: 80
#2Baek-Yeol Ryoo (Asan Medical Center)H-Index: 34
Last. Ann-Lii Cheng (NTU: National Taiwan University)H-Index: 90
view all 20 authors...
4004Background: Pembro received accelerated approval based on results of KEYNOTE-224, a phase 2 trial in pts with advanced HCC in the second line setting. KEYNOTE-240 (NCT02702401) was a randomized...
117 CitationsSource
#1Toshio TakagiH-Index: 21
#2Hironori FukudaH-Index: 8
Last. Kazunari TanabeH-Index: 54
view all 10 authors...
Background Patients in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate-risk group have heterogeneous prognoses and thus may benefit from improved risk stratification.
8 CitationsSource
#1Álvaro Díaz-González (University of Barcelona)H-Index: 9
#2Marco Sanduzzi-Zamparelli (University of Barcelona)H-Index: 5
Last. Maria Reig (University of Barcelona)H-Index: 33
view all 11 authors...
BACKGROUND: The positive results of the REFLECT trial in terms of survival (sorafenib vs lenvatinib) offer a new first-line option for hepatocellular carcinoma. Additionally, the expected results of immunotherapy could change the first-line treatment in hepatocellular carcinoma or the clinical trial design in first and second-line. AIMS: To evaluate the impact of dermatologic adverse events under sorafenib in hepatocellular carcinoma patients as a clinical marker to predict prognosis and critica...
29 CitationsSource
#1Andrew X. Zhu (Harvard University)H-Index: 97
#2Yoon-Koo Kang (Asan Medical Center)H-Index: 77
view all 24 authors...
Summary Background Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. Methods REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histolo...
560 CitationsSource
#1Jean-Luc RaoulH-Index: 72
#2Alejandro Forner (University of Barcelona)H-Index: 35
Last. Thierry de Baere (Institut Gustave Roussy)H-Index: 66
view all 6 authors...
Abstract Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with l...
94 CitationsSource
#1Stéphane Champiat (Université Paris-Saclay)H-Index: 27
#2Roberto Ferrara (Université Paris-Saclay)H-Index: 19
Last. Charles Ferté (Université Paris-Saclay)H-Index: 24
view all 7 authors...
Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall survival of a subset of patients across multiple solid tumour types, but other patients can have a deterioration of their disease as a result of such therapies. This paradoxical phenomenon is defined as hyperprogression. In this Review, we present the available evidence of hyperprogressive disease following immune-checkpoint inhibition, the pathophysiological hypotheses that might explain hyperprogressive disease and t...
175 CitationsSource
#1Nicholas C. Turner (UCLA: University of California, Los Angeles)H-Index: 64
#2Dennis J. Slamon (UCLA: University of California, Los Angeles)H-Index: 76
Last. Massimo Cristofanilli (UCLA: University of California, Los Angeles)H-Index: 100
view all 19 authors...
Abstract Background The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. We report the results of a prespecified analysis of overall survival. Methods We randomly assigned patients with hormone-receptor–positive, HER2-negative advanced breast cancer who had progression or relapse ...
361 CitationsSource
#1Michael J. Pishvaian (Georgetown University)H-Index: 31
#2Myung-Mook Lee (UNC: University of North Carolina at Chapel Hill)H-Index: 4
Last. Chun Hsu (NTU: National Taiwan University)H-Index: 11
view all 11 authors...
50 CitationsSource
Cited By67
Newest
#1Macarena Herranz-Itúrbide (University of Barcelona)
#2Irene Peñuelas-Haro (University of Barcelona)
Last. Isabel FabregatH-Index: 62
view all 5 authors...
The Transforming Growth Factor-beta (TGF-β) pathway plays essential roles in liver development and homeostasis and become a relevant factor involved in different liver pathologies, particularly fibrosis and cancer. The family of NADPH oxidases (NOXs) has emerged in recent years as targets of the TGF-β pathway mediating many of its effects on hepatocytes, stellate cells and macrophages. This review focuses on how the axis TGF-β/NOXs may regulate the biology of different liver cells and how this i...
Source
#1Blanca Cucarull (CSIC: Spanish National Research Council)H-Index: 3
#2Anna TutusausH-Index: 8
Last. Albert MoralesH-Index: 46
view all 0 authors...
Sorafenib and regorafenib, multikinase inhibitors (MKIs) used as standard chemotherapeutic agents for hepatocellular carcinoma (HCC), generate reactive oxygen species (ROS) during cancer treatment. Antioxidant supplements are becoming popular additions to our diet, particularly glutathione derivatives and mitochondrial-directed compounds. To address their possible interference during HCC chemotherapy, we analyzed the effect of common antioxidants using hepatoma cell lines and tumor spheroids. In...
Source
#2Gemma IserteH-Index: 1
Last. Maria Reig (University of Barcelona)H-Index: 33
view all 0 authors...
Abstract null null The landscape of hepatocellular carcinoma (HCC) has changed since the incorporation of sorafenib in 2007 as the first pharmacological treatment for HCC. The combination of atezolizumab plus bevacizumab is currently the first-line treatment for HCC patients, and there are several second-line options approved for patients who had received sorafenib as the first-line treatment. The advantage of having multiple options of pharmacological treatment for HCC patients is associated to...
Source
#1Chiun Hsu (New Generation University College)
#2Lorenza Rimassa (Humanitas University)H-Index: 32
Last. Ahmed Kaseb (University of Texas MD Anderson Cancer Center)H-Index: 29
view all 5 authors...
In light of positive efficacy and safety findings from the IMbrave150 trial of atezolizumab plus bevacizumab, this novel combination has become the preferred first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC). Several additional trials are ongoing that combine an immune checkpoint inhibitor with another agent such as a multiple kinase inhibitor or antiangiogenic agent. Therefore, the range of first-line treatment options for unresectable HCC is likely to in...
Source
#1Mincheng Yu (Fudan University)H-Index: 4
#2Guang-Yu Ding (Fudan University)H-Index: 5
Last. Hui-Chuan Sun (Fudan University)H-Index: 61
view all 12 authors...
Circular RNAs (circRNAs) are a class of regulatory RNAs with complex roles in healthy and diseased tissues. However, the oncogenic role of circRNAs in hepatocellular carcinoma (HCC) remains poorly understood, including the mechanisms by which the circular ubiquitin binding associated protein 2 (circUBAP2) contributes to tumorigenesis. We analyzed the expression of circUBAP2 in 20 paired samples of HCC and healthy tissue as well as in seven HCC cell lines via quantitative real-time polymerase cha...
Source
#1Robin Kate Kelley (UCSF: University of California, San Francisco)H-Index: 36
#2Bruno Sangro (University of Navarra)H-Index: 77
Last. Thomas Yau (QMUL: Queen Mary University of London)H-Index: 43
view all 24 authors...
PURPOSEThis phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monot...
4 CitationsSource
#1Fanhua Meng (Fudan University)
#2Biao Zou (Fudan University)
Last. Ting Qian (SJTU: Shanghai Jiao Tong University)
view all 5 authors...
BACKGROUND There are inconsistencies when concomitantly using dynamic contrast enhancement (DCE) and intravoxel incoherent motion (IVIM) to evaluate diagnostic efficiency. PURPOSE To evaluate the diagnostic efficiency of perfusion-related parameters in assessing the effect of Combretastatin-A4-phosphate (CA4P) in a rabbit VX2 liver tumor model using DCE and IVIM. MATERIAL AND METHODS Twenty rabbits implanted with VX2 tumors were included in the study. The perfusion-parameters of DCE (Ktrans and ...
Source
#1Yue Li (WHU: Wuhan University)H-Index: 2
#2Xiaoqin He (WHU: Wuhan University)H-Index: 5
Last. Ximing Xu (WHU: Wuhan University)H-Index: 12
view all 7 authors...
Genomic instability is a hallmark of all cancers. RMI2 is a crucial component of the BLM-TopoIIIa-RMI1-RMI2 complex that maintains genome stability. It has been shown to accelerate tumor progression in lung cancer, cervical cancer, and prostate cancer. However, its expression and function in hepatocellular carcinoma (HCC) remain poorly defined. In this study, gene expression data and corresponding clinical information of HCC were downloaded from the TCGA, ICGC, and GEO databases. The expression ...
Source
#1Jordi Bruix (University of Barcelona)H-Index: 115
#2Stephen L. Chan (CUHK: The Chinese University of Hong Kong)H-Index: 55
Last. Bruno Sangro (University of Navarra)H-Index: 77
view all 5 authors...
The last 5 years have witnessed relevant advances in the systemic treatment of hepatocellular carcinoma. New data have emerged since the development of the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma in 2018. Drugs licensed in some countries now include 4 oral multi-tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), 1 anti-angiogenic antibody (ramucirumab) and 4 immune checkpoint inhibitors, alone or in combination (atezolizumab ...
4 CitationsSource
#1Ester Gonzalez-Sanchez (ISCIII: Carlos III Health Institute)H-Index: 10
#2Javier Vaquero (ISCIII: Carlos III Health Institute)H-Index: 21
Last. Isabel Fabregat (University of Barcelona)H-Index: 62
view all 9 authors...
Transforming Growth Factor-beta (TGF-β) superfamily members are essential for tissue homeostasis and consequently, dysregulation of their signaling pathways contributes to the development of human diseases. In the liver, TGF-β signaling participates in all the stages of disease progression from initial liver injury to hepatocellular carcinoma (HCC). During liver carcinogenesis, TGF-β plays a dual role on the malignant cell, behaving as a suppressor factor at early stages, but contributing to lat...
1 CitationsSource